⚕️ Educational information only — not medical advice. Read the full disclaimer

Vitamin D and Arthritis: Does It Help Joint Pain?

Vitamin D is one of the most tested — and most over-promised — nutrients in arthritis. Low levels are common in people with osteoarthritis (OA) and rheumatoid arthritis (RA), and the biology linking vitamin D to bone, muscle and immune function is real. But when researchers gave vitamin D to people with knee OA in large, placebo-controlled trials, it did not ease pain or protect cartilage. This page explains what a 25(OH)D blood test actually tells you, why expert bodies disagree on the "right" level, what the trials in OA, RA and autoimmune disease show, who is genuinely at risk of deficiency, how much is safe, which medicines interact, and where the popular vitamin D + K2 pairing fits. The short version: correct a real deficiency; don't expect extra vitamin D to treat arthritis.

Important: This page is general educational information, not medical advice. Vitamin D testing, dosing and treatment of deficiency should be guided by a qualified clinician, particularly if you have kidney disease, sarcoidosis, a history of kidney stones or high calcium, or take prescription medication. Never stop or change a prescribed medication — including steroids, diuretics or arthritis drugs — without talking to your doctor or pharmacist.

Key takeaways

  • Correcting a true deficiency is well supported for bone and muscle health, and people with arthritis are often in higher-risk groups. Strong
  • Expert bodies disagree on the cut-off: the Institute of Medicine treats 20 ng/mL (50 nmol/L) as adequate; the Endocrine Society's 2011 guideline used 30 ng/mL; its 2024 guideline found no proven optimal level and advised against routine testing in people without a specific reason. Strong
  • Vitamin D supplements for knee OA: four randomized trials (up to three years, 146–1,398 people) found no benefit for pain or cartilage, and the ACR conditionally recommends against it. Contested
  • In the VITAL trial, 2,000 IU/day was linked to 22% fewer autoimmune diseases (including RA) — but the effect weakened on longer follow-up. Emerging
  • In established RA, small, mixed trials hint at modest improvements in disease-activity scores but not in blood inflammation markers. Emerging
  • More is not better: the adult upper limit is 4,000 IU/day without medical supervision, and excess causes hypercalcaemia; thiazide diuretics add to the risk. Strong

What vitamin D does in bones, muscles and immunity Strong (bone) Emerging (immune effects in arthritis)

Vitamin D is made in the skin when it is exposed to UVB sunlight and is found naturally in only a few foods — oily fish, egg yolks, and fortified milk, cereals or plant drinks. Its best-established job is to help the gut absorb calcium and phosphate, which bones need to stay mineralised. The US Institute of Medicine (IOM, now the National Academy of Medicine) reviewed the evidence in 2011 and concluded that vitamin D's role in skeletal health is consistent with cause and effect, whereas evidence for extraskeletal outcomes — including autoimmune disorders — was inconsistent and insufficient to set intake requirements.1

Mechanism: from sunlight to the vitamin D receptor

Vitamin D from skin or diet is converted in the liver to 25-hydroxyvitamin D [25(OH)D], the main circulating form and the one measured in blood tests. The kidneys (and some immune cells) then convert it to the active hormone 1,25-dihydroxyvitamin D, which acts through the vitamin D receptor found in bone, muscle, cartilage cells and many immune cells, including T cells and macrophages. Laboratory work suggests it can damp down inflammatory immune responses and the cartilage-degrading enzymes discussed on the root causes page — plausible mechanisms that, as the trials below show, have not translated into reliable joint benefits.14

Severe, long-standing deficiency causes osteomalacia in adults (soft bones) — a condition that itself causes diffuse bone pain, aching muscles and weakness that can be mistaken for arthritis or fibromyalgia. That overlap is one reason a vitamin D test is a reasonable part of a work-up for widespread aches in someone at risk.4

25(OH)D levels and why guidelines disagree Strong

Results are reported either in ng/mL (common in the US) or nmol/L (UK, Europe, Australia): multiply ng/mL by 2.5 to get nmol/L. The numbers below are where the major bodies land — and they do not agree, mainly because they were asking different questions.

Serum 25(OH)D levels and how different bodies interpret them
25(OH)DInterpretationSource
< 12 ng/mL (< 30 nmol/L)Risk of deficiency; associated with rickets and osteomalaciaIOM / NIH ODS4
< 20 ng/mL (< 50 nmol/L)Endocrine Society 2011: "deficient"; IOM: below the level that covers most people's bone needsEndocrine Society 20112; IOM1
≥ 20 ng/mL (≥ 50 nmol/L)IOM: meets the bone-health needs of at least 97.5% of the populationIOM 20111
21–29 ng/mL (52–72 nmol/L)Endocrine Society 2011: "insufficient"Endocrine Society 20112
≥ 30 ng/mL (≥ 75 nmol/L)Endocrine Society 2011: "sufficient" target for at-risk patientsEndocrine Society 20112
No defined targetEndocrine Society 2024: no clear evidence for an optimal level for disease prevention; suggests against routine testing without an established indicationEndocrine Society 20243
> 50 ng/mL (> 125 nmol/L)Flagged as potentially associated with adverse effects; no consistent extra benefitIOM / NIH ODS14
> 150 ng/mL (> 375 nmol/L)Hallmark of vitamin D toxicity from overdosingClinical review21

Why the disagreement? The IOM set population intake targets based on bone health and noted that higher levels were not consistently associated with greater benefit — some outcomes even showed U-shaped curves, with risk at both low and high levels. It also concluded that vitamin D inadequacy in North America had been overestimated.1 The Endocrine Society's 2011 guideline was written for clinicians treating patients at risk of deficiency and chose the higher 30 ng/mL bar; it recommended testing at-risk patients but not screening people who are not at risk.2 Its 2024 guideline took a different approach — reviewing randomized trials of disease prevention — and found no trial evidence to support routine 25(OH)D screening in the general population, nor in people with obesity or darker skin, and no clear evidence defining an optimal level. It suggests empiric (untested) vitamin D for children and adolescents, adults over 75, pregnancy and high-risk prediabetes, and suggests against doses above the dietary reference intakes for healthy adults under 75. The 2024 guideline explicitly does not apply to people with established reasons for testing or treatment.3

Holistic vs mainstream view: many integrative practitioners aim for 40–60 ng/mL or higher. That is practitioner opinion, not a guideline target — none of the major bodies above supports it, and trials have not shown that pushing levels that high improves arthritis. A well-founded reason to test (osteoporosis, long-term steroids, malabsorption, kidney or liver disease, unexplained bone pain) is a different matter; see biomarkers for how 25(OH)D fits with other markers.

Observational links with OA and RA — and reverse causation Emerging

Many studies find that people with low vitamin D have more joint problems. In osteoarthritis: in the Rotterdam Study (1,248 older adults followed for about 6.5 years), progression of knee OA on X-ray occurred in 12.6% of people in the lowest third of dietary vitamin D intake versus 5.1% in the highest, although neither intake nor blood levels predicted new knee OA.6 In a Tasmanian cohort of 769 adults aged 50–80, moderate deficiency (below 25 nmol/L, or 10 ng/mL) predicted worsening knee pain over five years — but there was no association across the range of levels, and only 4.2% of participants were that deficient.7

In rheumatoid arthritis: among 29,368 older women in the Iowa Women's Health Study, those with the highest vitamin D intake had about a third lower risk of developing RA (relative risk 0.67), which the authors themselves called hypothesis-generating.8 A meta-analysis of 24 reports (3,489 patients) found people with RA had lower vitamin D levels than healthy controls, and a weak inverse correlation between levels and disease activity (DAS28).9

The reverse-causation problem. A large systematic review of 290 prospective studies and 172 randomized trials found that low 25(OH)D is associated with a wide range of illnesses, but that supplementation trials generally did not prevent them. The authors concluded that low vitamin D is often a marker of ill health rather than its cause: inflammation itself lowers 25(OH)D, and people who are unwell or in pain go outdoors less, exercise less and may carry more weight.5 Arthritis fits this pattern — painful joints mean less time outside — which is why associations like those above cannot tell us whether supplements would help. Only randomized trials can.

Randomized trials in knee osteoarthritis Contested

Prompted by the observational data, several well-run trials tested whether vitamin D could slow knee OA. They were consistently negative for their main outcomes.

Major randomized trials of vitamin D in knee osteoarthritis
TrialWho and whatResult
McAlindon et al., JAMA 201310146 people with symptomatic knee OA; 2,000 IU/day, escalated to push 25(OH)D above 36 ng/mL; 2 yearsLevels rose by ~16 ng/mL, but knee pain and cartilage volume loss (MRI) were no different from placebo; no differences in function or other secondary outcomes
Jin et al., JAMA 201611413 people with knee OA and low vitamin D (12.5–60 nmol/L); 50,000 IU monthly; 2 yearsNo difference in tibial cartilage volume or WOMAC pain; more participants had adverse events on vitamin D (56 vs 37)
Arden et al. (VIDEO), Osteoarthritis Cartilage 201612474 adults over 50 with radiographic knee OA; 800 IU/day; 3 yearsNo difference in joint-space narrowing, pain, stiffness or function; no interaction with baseline vitamin D level
MacFarlane et al. (VITAL knee-pain subgroup), Arthritis Rheumatol 2020131,398 adults with chronic knee pain; 2,000 IU/day; mean 5.3 yearsNo difference in WOMAC pain, function or stiffness at any time point

A 2017 meta-analysis pooling four trials (1,136 patients) reported a statistically significant reduction in WOMAC pain and function scores, especially at doses above 2,000 IU/day, but no effect on cartilage volume; its authors still concluded there was not enough evidence to support vitamin D for slowing knee OA.14 That small pooled signal — against individually null, larger and longer trials — is why we grade the question Contested rather than settled. The 2019 American College of Rheumatology/Arthritis Foundation guideline conditionally recommends against vitamin D as an OA treatment.15 This matches our osteoarthritis and supplements pages.

What this means in practice: if you have OA and a measured deficiency, correcting it is sensible for bones, muscles and fall risk. But the treatments with strong evidence for OA pain are exercise and, where relevant, weight loss — not vitamin D.

VITAL: preventing autoimmune disease Emerging

The most intriguing vitamin D result for arthritis comes from prevention, not treatment. VITAL randomized 25,871 US adults (men 50 and over, women 55 and over; mean age 67) to 2,000 IU/day of vitamin D3 and/or 1,000 mg/day of marine omega-3, or placebo, in a two-by-two design. Over a median of 5.3 years, 123 people in the vitamin D group versus 155 on placebo developed a confirmed autoimmune disease — rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psoriasis and others — a 22% reduction (hazard ratio 0.78, 95% CI 0.61–0.99, P = 0.05). Omega-3 alone showed a 15% reduction that was not statistically significant.16

Two caveats keep this at Emerging. First, in a follow-up report that confirmed additional cases with onset during the trial, the vitamin D result weakened to a non-significant hazard ratio of 0.85 (95% CI 0.70–1.04). Second, two years after participants stopped their pills, the vitamin D group's advantage had disappeared (hazard ratio 0.98), whereas the omega-3 group's reduction persisted (0.83).17 VITAL was also not designed or powered to look at RA alone, and its participants were not selected for low vitamin D. The finding is promising and biologically plausible, but it comes from one trial and needs replication before anyone can say vitamin D prevents RA.

A related VITAL analysis is a useful reality check on "vitamin D for bones": among the same 25,871 generally healthy adults, 2,000 IU/day did not reduce total, non-vertebral or hip fractures (hazard ratio 0.98 for total fractures), regardless of baseline vitamin D level.19 Benefits for bone are clearest in people who are actually deficient or at high fracture risk.

Vitamin D in established rheumatoid arthritis Emerging

Trials in people who already have RA are smaller and more varied. A 2024 systematic review and dose-response meta-analysis of 11 randomized trials found that vitamin D did not significantly lower CRP or ESR, but did modestly reduce pain on a visual analogue scale and the DAS28 disease-activity score (by about 0.58 points). The trials differed widely in dose, baseline vitamin D, duration and background treatment, and heterogeneity was high, so the authors called for better-controlled studies.18

For perspective, a change of about 0.6 in DAS28 is noticeable but smaller than the effect expected from disease-modifying drugs. Vitamin D is best seen as possibly helpful alongside rheumatology care — especially because people with RA often have several reasons to be low (less sun exposure, steroid use, reduced activity) and are at higher risk of osteoporosis. See the rheumatoid arthritis page for other complementary measures.

Do not replace RA medication with supplements. RA can damage joints permanently within months if it is undertreated. Vitamin D is not a substitute for methotrexate, biologics or other DMARDs; discuss any supplement with your rheumatologist.

Who is at risk of deficiency? Strong

Testing makes the most sense when there is a reason to suspect deficiency or a condition where vitamin D status changes management. Groups at higher risk include:24

Higher-risk situations

  • Little sun exposure: housebound, care-home residents, covered clothing, northern latitudes in winter
  • Darker skin, which makes less vitamin D from the same sunlight
  • Older age — the skin synthesises less, and intake is often low
  • Obesity or a history of gastric bypass surgery
  • Fat malabsorption: coeliac disease, Crohn's disease, cystic fibrosis, some liver disease
  • Chronic kidney or liver disease
  • Breastfed infants without supplementation

Arthritis-specific reasons to ask

  • Long-term oral corticosteroids (prednisone/prednisolone)22
  • Osteoporosis, previous fragility fracture or falls
  • Reduced mobility from painful joints, so less time outdoors
  • Widespread bone pain or muscle weakness that could be osteomalacia
  • Thiazide diuretics or other medicines that interact with vitamin D (see interactions)

Safe intake, upper limits and toxicity Strong

600 IURDA, ages 1–70 (15 µg/day)1
800 IURDA, age 71+ (20 µg/day)1
4,000 IUAdult upper limit (100 µg/day) without supervision4
>150ng/mL 25(OH)D: typical of toxicity21

The IOM's Recommended Dietary Allowances — 600 IU/day up to age 70 and 800 IU/day from 71 — were set assuming minimal sun exposure and correspond to a 25(OH)D of at least 20 ng/mL.1 The adult Tolerable Upper Intake Level is 4,000 IU (100 µg) a day from all sources; clinicians sometimes prescribe more for a limited time to correct a measured deficiency, with follow-up testing.4 One microgram equals 40 IU.

Daily beats mega-doses. In an Australian trial of 2,256 women aged 70 and over, a single yearly dose of 500,000 IU increased falls by 15% and fractures by 26% compared with placebo, with the excess concentrated in the first three months after each dose.20 The Endocrine Society's 2024 guideline likewise suggests daily rather than intermittent high-dose vitamin D for people over 50 who need it.3

Vitamin D toxicity and hypercalcaemia. Too much vitamin D raises blood calcium. Symptoms include confusion, apathy, recurrent vomiting, abdominal pain, excessive urination and thirst, and dehydration; untreated, it can cause kidney stones, kidney injury and heart-rhythm problems. Toxicity from supplements is rare and usually follows long-term intake of very high doses — sometimes from mislabelled or mis-dosed products — but some people develop high calcium at much lower doses. These include people with sarcoidosis or other granulomatous diseases, some lymphomas, and rare genetic conditions, because their bodies make excess active vitamin D.21 If you take vitamin D and develop these symptoms, seek medical care and mention the supplement.

Sunlight does not cause vitamin D toxicity, because the skin limits its own production — but it carries skin-cancer risk, which is why the IOM based its recommendations on minimal sun exposure.1

Medication interactions Strong

Interactions run both ways: some drugs lower vitamin D, and vitamin D can change how some drugs behave. A systematic review of drug–vitamin D interactions found that most of the evidence is of modest quality — for several drug classes, including anti-seizure drugs, it was insufficient to say whether they change vitamin D levels — while flagging the thiazide–calcium combination as a clinical concern.23

Medications that interact with vitamin D
MedicationInteractionWhat to do
Oral corticosteroids (prednisone, prednisolone)Reduce calcium absorption and impair vitamin D metabolism; in US national data, recent steroid users had about twice the odds of 25(OH)D below 10 ng/mL224Long-term users should ask about bone protection, including vitamin D and calcium status — see corticosteroids and bone
Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide)Reduce urinary calcium excretion; combined with vitamin D and calcium supplements can cause hypercalcaemia, especially in older adults, people with reduced kidney function or hyperparathyroidism234Tell your prescriber before starting vitamin D or calcium; periodic calcium checks may be needed
Orlistat (weight-loss drug)Reduce absorption of fat-soluble vitamins, including D4Ask your pharmacist about timing and whether levels should be checked
Statins (e.g. atorvastatin)Limited evidence that vitamin D supplements may lower atorvastatin concentrations; atorvastatin may raise 25(OH)D23Clinical importance unclear; mention supplements at medication reviews
Never stop or change these medicines on your own. Steroids in particular must not be stopped suddenly. If you take any of them, ask your doctor or pharmacist whether vitamin D testing or supplementation is appropriate. More on drug effects on nutrients is on the medications page.

Vitamin D + K2: what the claims rest on Contested

Vitamin D and K2 (menaquinone, often as MK-7) are widely sold together, with the claim that K2 "directs" the extra calcium absorbed thanks to vitamin D into bone and away from arteries and joints. The idea draws on real biology: vitamin K activates matrix Gla protein, which inhibits calcification of cartilage and blood vessels (see the root causes page).

The evidence for joints is thin. In the Framingham Offspring cohort (672 people), lower blood vitamin K levels were associated with more hand and knee OA features on X-ray.24 But in a three-year randomized trial of 378 older adults, vitamin K1 (phylloquinone) supplements had no overall effect on hand OA; a possible benefit was seen only in a subgroup who started insufficient and became sufficient.25 We found no robust randomized trials showing that a vitamin D + K2 combination improves arthritis pain or progression. The combination is reasonable to discuss for people with a specific reason to take both, but it should be presented as a hypothesis, not a joint treatment.

Warfarin warning: vitamin K — including K2 in "D3 + K2" products — counteracts warfarin (Coumadin) and can make it less effective, raising clot risk. If you take warfarin, talk to your prescriber before starting, stopping or changing any vitamin K product. Strong

Putting it together: a practical approach

Vitamin D and arthritis: what the evidence supports
QuestionBottom lineEvidence
Correcting a measured deficiencySupported for bone and muscle health; reasonable in anyone with arthritis who is deficientStrong
Vitamin D to treat knee OA pain or slow cartilage lossLarge trials null; one meta-analysis shows a small pain signal; ACR recommends againstContested
Vitamin D to prevent RA or other autoimmune diseaseOne large trial positive; effect weakened on follow-up and faded after stoppingEmerging
Vitamin D as an add-on in established RASmall, heterogeneous trials; modest DAS28 and pain improvements, no change in CRP/ESREmerging
Aiming for 40–60+ ng/mLPractitioner opinion; no guideline or trial support for arthritisContested
Vitamin D + K2 for jointsPlausible mechanism; no convincing joint trialsContested
Staying within 4,000 IU/day unless supervisedAvoids hypercalcaemia; mega-doses can backfireStrong

A balanced approach: get vitamin D from sensible sun exposure, oily fish and fortified foods; ask your doctor about testing if you are in a higher-risk group or take long-term steroids; if you are deficient, correct it with a daily dose agreed with your clinician; and put most of your effort into the measures with strong evidence for joints — exercise, weight management and, for inflammatory arthritis, prompt medical treatment. Other supplements are compared on the supplements page.

Dietary & supplement note: Statements here about foods and dietary supplements have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease.

When to see a doctor Strong

Seek prompt medical care if you:
  • take vitamin D and develop confusion, repeated vomiting, severe thirst, passing large amounts of urine, abdominal pain or marked weakness — signs of high calcium;
  • have a hot, red, swollen joint, especially with fever — this needs same-day assessment to rule out infection or gout;
  • have new joint swelling and morning stiffness lasting more than 30 minutes in several joints for over six weeks — possible inflammatory arthritis, where early treatment matters;
  • have bone pain, a fracture after a minor fall, or new difficulty rising from a chair or climbing stairs.

Book a routine appointment to discuss vitamin D if you:

  • are in one of the higher-risk groups above;
  • take long-term steroids, orlistat or a thiazide diuretic and want to start a supplement;
  • have kidney disease, sarcoidosis, a history of kidney stones or high calcium;
  • are taking more than 4,000 IU/day, or several products that each contain vitamin D.

Frequently asked questions

Does vitamin D help joint pain or arthritis?

Correcting a true deficiency is well supported for bone and muscle health. But in randomized trials of people with knee osteoarthritis — including two-year trials in JAMA in 2013 and 2016 — vitamin D did not reduce knee pain or slow cartilage loss compared with placebo, and the American College of Rheumatology conditionally recommends against it as an OA treatment. In rheumatoid arthritis, small trials suggest possible modest improvements in disease-activity scores, but results are inconsistent. This is educational information, not medical advice.

What vitamin D level is normal?

Guidelines disagree. The Institute of Medicine (2011) concluded that a 25(OH)D level of at least 20 ng/mL (50 nmol/L) meets the bone-health needs of at least 97.5% of people. The Endocrine Society's 2011 guideline used 30 ng/mL (75 nmol/L) as sufficient. Its 2024 guideline found no clear evidence for an optimal level for disease prevention and suggested against routine testing in people without a specific reason. Levels above about 50 ng/mL (125 nmol/L) have been flagged as potentially linked to harm, and toxicity is typically seen above 150 ng/mL (375 nmol/L). Your doctor should interpret your result.

Can vitamin D prevent rheumatoid arthritis or autoimmune disease?

Possibly, but it is not settled. In the VITAL trial of 25,871 older US adults, 2,000 IU daily for about five years was associated with 22% fewer confirmed autoimmune diseases (hazard ratio 0.78). In a follow-up report, counting extra cases confirmed later weakened the in-trial result to a non-significant hazard ratio of 0.85, and the benefit faded within two years of stopping. The trial was not designed specifically for rheumatoid arthritis.

How much vitamin D is too much?

The Tolerable Upper Intake Level for adults is 4,000 IU (100 µg) a day from all sources, unless a clinician supervises a higher dose to treat a measured deficiency. Excess vitamin D raises blood calcium, which can cause nausea, vomiting, confusion, excessive thirst and urination, kidney stones and kidney injury. People with kidney disease, sarcoidosis or other granulomatous conditions, or who take thiazide diuretics are at higher risk and should only supplement under medical guidance.

Should I take vitamin K2 with vitamin D for my joints?

The idea that K2 steers calcium into bone and away from joints and arteries is biologically plausible, and low vitamin K status is linked with osteoarthritis in observational studies. However, there are no good randomized trials showing that a vitamin D plus K2 combination improves arthritis, and a three-year trial of vitamin K1 found no overall effect on hand osteoarthritis. Vitamin K counteracts warfarin, so anyone on warfarin must talk to their prescriber first.

References

  1. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–58. PubMed 21118827
  2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930. PubMed 21646368
  3. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907–1947. PubMed 38828931
  4. Vitamin D — Fact Sheet for Health Professionals. NIH Office of Dietary Supplements. ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
  5. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2(1):76–89. PubMed 24622671
  6. Bergink AP, Uitterlinden AG, Van Leeuwen JP, et al. Vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee: the Rotterdam Study. J Clin Rheumatol. 2009;15(5):230–237. PubMed 19654490
  7. Laslett LL, Quinn S, Burgess JR, et al. Moderate vitamin D deficiency is associated with changes in knee and hip pain in older adults: a 5-year longitudinal study. Ann Rheum Dis. 2014;73(4):697–703. PubMed 23595144
  8. Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 2004;50(1):72–77. PubMed 14730601
  9. Lin J, Liu J, Davies ML, Chen W. Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One. 2016;11(1):e0146351. PubMed 26751969
  10. McAlindon T, LaValley M, Schneider E, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA. 2013;309(2):155–162. PubMed 23299607
  11. Jin X, Jones G, Cicuttini F, et al. Effect of vitamin D supplementation on tibial cartilage volume and knee pain among patients with symptomatic knee osteoarthritis: a randomized clinical trial. JAMA. 2016;315(10):1005–1013. PubMed 26954409
  12. Arden NK, Cro S, Sheard S, et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. Osteoarthritis Cartilage. 2016;24(11):1858–1866. PubMed 27264058
  13. MacFarlane LA, Cook NR, Kim E, et al. The effects of vitamin D and marine omega-3 fatty acid supplementation on chronic knee pain in older US adults: results from a randomized trial. Arthritis Rheumatol. 2020;72(11):1836–1844. PubMed 32583982
  14. Gao XR, Chen YS, Deng W. The effect of vitamin D supplementation on knee osteoarthritis: a meta-analysis of randomized controlled trials. Int J Surg. 2017;46:14–20. PubMed 28797917
  15. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020;72(2):149–162. PubMed 31908149
  16. Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452. PubMed 35082139
  17. Costenbader KH, Cook NR, Lee IM, et al. Vitamin D and marine n-3 fatty acids for autoimmune disease prevention: outcomes two years after completion of a double-blind, placebo-controlled trial. Arthritis Rheumatol. 2024;76(6):973–983. PubMed 38272846
  18. Al-Saoodi H, Kolahdooz F, Andersen JR, Jalili M. Effect of vitamin D on inflammatory and clinical outcomes in patients with rheumatoid arthritis: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Rev. 2024;82(5):600–611. PubMed 37437898
  19. LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med. 2022;387(4):299–309. PubMed 35939577
  20. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815–1822. PubMed 20460620
  21. Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, Płudowski P, Jones G. Vitamin D toxicity — a clinical perspective. Front Endocrinol (Lausanne). 2018;9:550. PubMed 30294301
  22. Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001–2006. J Clin Endocrinol Metab. 2011;96(12):3838–3845. PubMed 21956424
  23. Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug–vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;28(2):194–208. PubMed 23307906
  24. Neogi T, Booth SL, Zhang YQ, et al. Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthritis Rheum. 2006;54(4):1255–1261. PubMed 16572460
  25. Neogi T, Felson DT, Sarno R, Booth SL. Vitamin K in hand osteoarthritis: results from a randomised clinical trial. Ann Rheum Dis. 2008;67(11):1570–1573. PubMed 18625626